Metabolic
Tesa
Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog used primarily to reduce excess visceral abdominal fat. It is FDA-approved for HIV-associated lipodystrophy and increasingly used off-label in anti-aging or metabolic medicine to improve body composition. It works by naturally stimulating the pituitary gland.
Mechanism of Action
Research indicates that tesamorelin binds the growth-hormone-releasing hormone (GHRH) receptor on pituitary somatotroph cells, a G-protein-coupled receptor whose activation elevates intracellular cyclic AMP and promotes the synthesis and pulsatile secretion of endogenous growth hormone (GH). Because it engages the native GHRH pathway rather than supplying exogenous GH, it is studied as an agent that stimulates the body's own GH output while nominally preserving physiological feedback and pulsatility.
Research further indicates that the defining structural feature is N-terminal stabilization: a trans-3-hexenoyl (hexenoic acid) group attached to the peptide is reported to reduce cleavage by dipeptidyl peptidase-IV (DPP-IV), the enzyme that rapidly degrades native GHRH, thereby extending the analog's functional half-life in circulation. Downstream, GH released in response to receptor activation is understood to drive hepatic and peripheral production of insulin-like growth factor 1 (IGF-1), which is commonly used in research as a marker of somatotropic-axis engagement. These statements describe mechanistic and pharmacological observations only and are not claims of clinical benefit.
Research Applications
- → Characterized as a stabilized full-length analog of human GHRH(1-44) bearing an N-terminal trans-3-hexenoyl modification.
- → The N-terminal acyl group is reported to reduce dipeptidyl peptidase-IV (DPP-IV) cleavage, a modification associated with extended plasma half-life relative to native GHRH.
- → Acts as an agonist at the pituitary GHRH receptor, stimulating endogenous growth-hormone synthesis and pulsatile release rather than supplying exogenous GH.
- → Receptor engagement is reported to increase circulating IGF-1, a downstream marker used to index somatotropic-axis activation in research models.
- → Studied in controlled research settings for effects on body composition, notably visceral adipose tissue, without the direct exogenous-GH dosing used in comparison approaches.
Analytical Validation
Tesa is verified via LC-MS and HPLC analysis. Each lot is tested for identity, purity (≥99% target), and endotoxin levels. Full certificate of analysis is available upon request.
